Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Stroup, T. S. Search for Related Content PubMed Citation Articles by Stroup, T. S. Schizophrenia Spectrum Disorders Atypical Neuroleptics Related Article

Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic

Background: In the treatment of schizophrenia, changing antipsychotics is common when one treatment is suboptimally effective, but the relative effectiveness of drugs used in this strategy is unknown. This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic. METHOD: Subjects with schizophrenia (N=444) who had discontinued the atypical antipsychotic randomly assigned during phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigation were randomly reassigned to double-blind treatment with a different antipsychotic (olanzapine, 7.5–30 mg/day [N=66]; quetiapine, 200–800 mg/day [N=63]; risperidone, 1.5–6.0 mg/day [N=69]; or ziprasidone, 40–160 mg/day [N=135]). The primary aim was to determine if there were differences between these four treatments in effectiveness measured by time until discontinuation for any reason. RESULTS: The time to treatment discontinuation was longer for patients treated with risperidone (median: 7.0 months) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months). Among patients who discontinued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more effective than quetiapine. There were no significant differences between antipsychotics among those who discontinued their previous treatment because of intolerability (N=168). CONCLUSIONS: Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A50. [Full Text] [PDF]

This article has been cited by other articles:

				M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman What CATIE Found: Results From the Schizophrenia Trial Psychiatr Serv, May 1, 2008; 59(5): 500 - 506. [Abstract] [Full Text] [PDF]

				N. H. Covell, M. T. Finnerty, and S. M. Essock Implications of CATIE for Mental Health Services Researchers Psychiatr Serv, May 1, 2008; 59(5): 526 - 529. [Abstract] [Full Text] [PDF]

				J. J. Parks, A. Q. Radke, and R. Tandon Impact of the CATIE Findings on State Mental Health Policy Psychiatr Serv, May 1, 2008; 59(5): 534 - 536. [Abstract] [Full Text] [PDF]

				J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment Schizophr Bull, April 2, 2008; (2008) sbn019v1. [Abstract] [Full Text] [PDF]

				R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak Rethinking Antipsychotic Formulary Policy Schizophr Bull, March 1, 2008; 34(2): 375 - 380. [Abstract] [Full Text] [PDF]

				T. S. Stroup and J. R. Geddes Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals Schizophr Bull, March 1, 2008; 34(2): 266 - 274. [Abstract] [Full Text] [PDF]

				Bibliography Schizophrenia Focus, January 1, 2008; 6(2): 197 - 199. [Full Text] [PDF]

				P. D. Taylor Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia Evid. Based Ment. Health, August 1, 2007; 10(3): 76 - 76. [Full Text] [PDF]

				N. A. KEKS, M. INGHAM, A. KHAN, and K. KARCHER Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study The British Journal of Psychiatry, August 1, 2007; 191(2): 131 - 139. [Abstract] [Full Text] [PDF]

				J. P. McEvoy, J. A. Lieberman, D. O. Perkins, R. M. Hamer, H. Gu, A. Lazarus, D. Sweitzer, C. Olexy, P. Weiden, and S. D. Strakowski Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison Am J Psychiatry, July 1, 2007; 164(7): 1050 - 1060. [Abstract] [Full Text] [PDF]

				C. A. Tamminga and J. M. Davis The Neuropharmacology of Psychosis Schizophr Bull, July 1, 2007; 33(4): 937 - 946. [Abstract] [Full Text] [PDF]

				R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial Arch Gen Psychiatry, June 1, 2007; 64(6): 633 - 647. [Abstract] [Full Text] [PDF]

				S. R. Marder Lessons From Each Drug Trial Am J Psychiatry, March 1, 2007; 164(3): 375 - 376. [Full Text] [PDF]

				J. Lauriello Great(er) Expectations Am J Psychiatry, March 1, 2007; 164(3): 377 - 379. [Full Text] [PDF]

				T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, G. A. Capuano, R. A. Rosenheck, R. S.E. Keefe, A. L. Miller, I. Belz, et al. Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study Am J Psychiatry, March 1, 2007; 164(3): 415 - 427. [Abstract] [Full Text] [PDF]

				M. S. Swartz, D. O. Perkins, T. S. Stroup, S. M. Davis, G. Capuano, R. A. Rosenheck, F. Reimherr, M. F. McGee, R. S.E. Keefe, J. P. McEvoy, et al. Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study Am J Psychiatry, March 1, 2007; 164(3): 428 - 436. [Abstract] [Full Text] [PDF]

				B. L. Herbel and H. Stelmach Involuntary Medication Treatment for Competency Restoration of 22 Defendants With Delusional Disorder J Am Acad Psychiatry Law, March 1, 2007; 35(1): 47 - 59. [Abstract] [Full Text] [PDF]

				S. Bleakley, O. Olofinjana, and D. Taylor Which antipsychotics would mental health professionals take themselves? Psychiatr. Bull., March 1, 2007; 31(3): 94 - 96. [Abstract] [Full Text] [PDF]

				S. M. Essock, N. H. Covell, S. M. Davis, T. S. Stroup, R. A. Rosenheck, and J. A. Lieberman Effectiveness of Switching Antipsychotic Medications Am J Psychiatry, December 1, 2006; 163(12): 2090 - 2095. [Abstract] [Full Text] [PDF]

				W. T Carpenter Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone. Evid. Based Ment. Health, November 1, 2006; 9(4): 106 - 106. [Full Text] [PDF]

				Bibliography PSYCHOPHARMACOLOGY Focus, September 1, 2006; 4(4): 512. [Full Text] [PDF]

				T. S. Stroup, J. A. Lieberman, J. P. McEvoy, M. S. Swartz, S. M. Davis, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, C. E. Davis, J. Severe, et al. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic Focus, September 1, 2006; 4(4): 539. [Full Text] [PDF]

				R. Ganguli and M. Strassnig Are older antipsychotic drugs obsolete? BMJ, June 10, 2006; 332(7554): 1346 - 1347. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us